Butantane vaccine against dengue fever shows 79.6% efficacy in study

The Butantane Institute published the first results of phase 3 clinical trials of the dengue vaccine Butantan-DV (in humans) this Friday (16), in a study conducted since 2010. In a two-year follow-up with more than 16 thousand people across Brazil, The effectiveness of the vaccine in preventing the disease was 79.6%🇧🇷

After the 1st phase developed in the USA between 2010-2012 and the 2nd phase carried out in Brazil between 2013-2015, the 3rd phase of the clinical trial continuing in our country includes 16,235 volunteers aged 2 to 59 years in 16 research centers from various countries. . regions. The vaccine was administered to 10 thousand 259 people as a single dose. the rest took a placebo to compare results.

quadrivalent dengue vaccine

During the period under review, no serious cases of dengue fever were reported in the participants🇧🇷 The positive result came amid the boom in dengue cases in Brazil. According to the Ministry of Health, by December 2022, more than 1.4 million cases and 978 deaths from the disease were registered, an increase of 172.4% and 400% compared to the previous year.

Butantan-DV is a quadrivalent vaccineThis means that although only the first two were circulating in the country at the time of research, its aim was to protect against the four serotypes of dengue virus (DENV-1, DENV-2, DENV-3 and DENV-4). Efficacy against both was 89.5% and 69.6%, respectively.

During phase 3, which is still ongoing, the researchers also want to generate efficacy data for serotypes 3 and 4.